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Abstract
Background: Most patients with cancers of the nasal cavity or paranasal sinuses are candidates of radiation
therapy either due incomplete resection or technical inoperability. Local control in this disease is dose dependent
but technically challenging due to close proximity of critical organs and accompanying toxicity. Modern techniques
such as IMRT improve toxicity rates while local control remains unchanged. Raster-scanned carbon ion therapy
with highly conformal dose distributions may allow higher doses at comparable or reduced side-effects.
Methods/design: The IMRT-HIT-SNT trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary
endpoint: mucositis ≥ CTCAE°III) and efficacy (secondary endpoint: local control, disease-free and overall survival) in
the combined treatment with IMRT and carbon ion boost in 30 patients with histologically proven (≥R1-resected
or inoperable) adeno-/or squamous cell carcinoma of the nasal cavity or paransal sinuses. Patients receive 24 GyE
carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).
Discussion: The primary objective of IMRT-HIT-SNT is to evaluate toxicity and feasibility of the proposed treatment
in sinonasal malignancies.
Trial Registration: Clinical trial identifier NCT 01220752
Background
Sinonasal malignancies are a heterogeneous group of
tumours of the nasal cavity and paranasal sinuses
accounting for about 5% of head and neck tumours and
1% of all cancers [1,2]. Most commonly, these are ade-
nocarcinomas and squamous cell carcinomas, however
also rare tumours such as adenoidcystic carcinomas,
aesthesioneuroblastoma, sarcomas, melanomas, and
other rare histologies are occasionally found in the nasal
cavity and paranasal sinus [3]. Malignant sinonasal
tumours are often asymptomatic until late in the course
of the disease, therefore patients frequently present with
extensive tumours displacing adjacent organs or infil-
trating surrounding tissues. Due to the proximity of
critical organs such as eyes, optic nerves, chiasm, lacri-
mal gland, temporal lobe, and pituary gland complete
resection of these tumours is rarely possible. In addition,
surgical en-bloc resections are impossible in this area of
the body, which is another reason why surgical resection
margins in locally advanced tumours are rarely free.
Extensive surgical procedures are also severely mutilat-
ing if a radical maxillectomy or orbital exenteration are
necessary to remove the tumour. Chemotherapy for the
treatment of sinunasal malignancies is still under discus-
sion, however, recent results showed a significant advan-
tage for postoperative adjuvant chemotherapy either
alone or in combination with radiotherapy [4].
In view of the rarely complete surgical therapy, most
patients will undergo radiation therapy at one point in
the course of their treatment. Maximal surgical resec-
tion followed by adjuvant conventional radiotherapy
leads to a local control of 59% and an overall survival of
40% at 5 years [5]. Unfortunately, conventional radio-
therapy has led to therapy-induced loss of vision in
approximately one third of the treated patients [6,7].
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ticated radiotherapy techniques. 3D conformal and
intensity-modulated (IMRT) radiotherapy allow more
conformal dose distributions and hence improved
normal tissue sparing. Various planning studies were
already able to demonstrate that especially patients with
sinunasal tumours highly profit from modern RT-tech-
niques [8-13]. Chen et al performed a retrospective ana-
lysis over five decades in their institution and could
impressively show that also in practice introduction of
new radiotherapy treatment techniques led to reduction
of accompanying side-effects [14,15].
Recent clinical data though are showing promising
results. Hoppe et al treated 37 patients with sinunasal
malignancies with postoperative IMRT to a median dose
of 60 Gy [16]. This treatment resulted in 2-year progres-
sion-free survival of 75% and an overall survival of 80%.
At a median follow-up of 28 months, no grade 3/4 toxi-
city of the eyes or visual pathway was seen [16]. Another
trial included 84 patients with various histologies of the
paranasal sinuses also treating these patients with IMRT
to a total dose of 70 Gy in 35 fractions either in the
postoperative or definitive situation [3]. In this study,
actuarial local control at 5 years was 70,7% with an
overall survival of 67% at the time of analysis. Nineteen
out of the 84 patients developed local recurrences of
their tumour. Multivariate analysis was able to identify
invasion of the cribriform plate and anterior cranial
fossa as a significant predictor of lower local control
[3,17]. Compared to Hoppe et al [16], dose escalation to
70 Gy in the Madani-series led to a higher rate of radio-
genic early and late toxicity including increased rates of
grade 2/3 eye-and optic nerve injury as well as high
rates of grade 2/3 mucositis in this cohort [3]. In unre-
sectable sinunasal tumours however, also Hoppe et al
reported significant rates of acute and late toxicity [18]:
two out of 39 patients developed radionecrosis while
one patient suffered from unilateral loss of vision 7
years after RT with a dose of approximately 77 Gy to
the optic nerve. However, thep r o g n o s t i cp a r a m e t e rf o r
overall survival and local control were found to be
T-stage [19] a total dose of >65 Gy [18]. Local failure
within the high-dose area remains the predominant site
o fr e l a p s e[ 2 0 , 2 1 ]h e n c eu n d e r l i n i n gt h en e e df o rm o r e
aggressive treatment regimen. Therefore treatment con-
cepts for these tumours remain a challenge: radiation
oncologists and patients are confronted with the choice
of either applying high radiation doses at the cost of
significant side-effects or keeping side-effects low and
risking higher rates of local relapse. In this situation
though, particle therapy with highly conformal dose dis-
tributions and increased biological effectiveness might
b eaw a yo u to ft h ed i l e m m aa n di n c r e a s et h e r a p e u t i c
range. Initial steps have been made with a phase I/II
trial using combined photon-/proton therapy [22].
Locally advanced paransal sinus tumours received a
median total dose of 73.6 Gy yielding an actuarial local
control of 82% at 5 years and an overall survival of 58%
in this cohort [22]. Updated results of a larger patient
cohort even showed 2-year local control rates of 86% at
the cost of 25% grade III mucositis and 10% grade 2
ocular late toxicity [17].
Mucositis ≥ CTCAE°III is a very painful radiogenic
acute toxicity leading to significant reduction of the
patients’ quality of life. In addition, higher grade muco-
sitis may also lead to increased hospital admission for
intensive supportive therapy including cost-intensive
parenteral feeding. In addition, severe mucositis also
leads to an increased number of therapy interruptions
or even discontinuation of therapy and hence worsening
o therapeutic outcome. In cases where additional
chemotherapy is applied concomitantly, it is even more
important to keep radiation-induced mucositis to a
minimum to maintain compliance with the treatment
regimen.
Both carbon ion therapy and IMRT have the potential
to reduce normal tissue injury while allowing dose escala-
tion within the tumour or prior tumour bed. The present
trial (IMRT-HIT-SNT) was therefore designed to evaluate
toxicity with special focus on mucositis ≥ CTCAE°III and
efficacy in combined intensity-modulated RT and carbon
ion boost.
Methods/design
Study design
The IMRT-HIT-SNT trial is a prospective, non-rando-
mized phase II feasibility trial evaluating acute mucositis ≥
CTCAE°III as the primary endpoint.
Study Characteristics
Based on the fact that local control seems to be dose-
dependent and local failure within the high-dose area
remains the predominant site of relapse [20,21], the
combination of IMRT (50 Gy in 2 Gy/fraction) and
C12-boost (24 GyE in 3 GyE/fraction) will be tested as to
toxicity profile and efficacy.
Study objectives
To evaluate feasibility and toxicity (with a focus on
mucositis CTCAE °III) and efficacy of the treatment.
Incidence of mucositis ≥ CTC°III will be assessed as the
primary endpoint of the trial, local control, disease-free
survival, overall survival, toxicity (incl. mucositis CTCAE
°I-II and late toxicity at 2 years post RT).
Sample size/number of subjects
Incidence of mucositis CTC°III in the reported data was
14.1% for IMRT to similar total doses [3]. As described
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tion of mucositis rates as compared to previous reports.
We assume the new therapy to be clinically irrelevant if
the incidence of mucositis ≥CTCAE°III is higher than
30% whereas the experimental therapy is clinically feasi-
ble and warranting further investigation if the rate of
mucositis ≥CTCAE°III is less than 10% and hence more
than 90% of patients do not experience a mucositis
≥CTCAE°III. Using Simons Two-stage-Design (a = 0.05;
Power 80%) a sample size of 30 patients was caluclated
assuming a drop out rate of 10%. In the first stage, a
maximum of 2 out of 6 patients may show a mucositis
≥CTCAE°III, and 5 out of 27 patients in total [23].
Patient selection
Inclusion criteria
￿ Histologically confirmed or incompletely resected ade-
nocarcinoma or squamous cell carcinoma of the nasal
cavity or paranasal sinuses
￿ Inoperable tumour or refusal to undergo surgical
resection
￿ Macroscopic or microscopic residual tumour (R2/
R1) or
￿ ≥T3/T4 or
￿ written informed consent
￿ pts aged 18 - 80 years
￿ effective contraception for pts in childbearing age
(<12 months post beginning of menopause)
Exclusion criteria
￿ Prior radio- or chemotherapy for tumours of the head
and neck
￿ Other previous malignancy within the past 5 years
except prior, adequately treated basal cell carcinoma of
the skin or pre-invasive carcinoma of the cervix
￿ Significant neurological or psychiatric condition
including dementia or seizures or other serious medical
condition prohibiting the patient’s participation in the
trial by judgement of the investigators
￿ Legal incapacity or limited legal capacity
￿ Positive serum/urine b-HCG/pregnancy
￿ Drug abuse
Radiotherapy
Immobilisation/planning examinations
Patients are immobilized using individual thermoplastic
head masks with thermoplastic shoulder fixation. Plan-
ning examinations consist of a planning CT scan (3 mm
slice thickness) with the patient positioned in the indivi-
dual fixation device and contrast-enhanced MRI for 3D
image correlation.
Target volumes/dose prescription
CTV1 (carbon ion boost) includes the macroscopic
tumour, positive lymph nodes and prior tumour bed
with special focus on the R1-area. PTV1 consists of a 2
mm margin around the CTV1 but does not extend into
critical organs at risk (i.e. brain stem, spinal cord).
We prescribe a dose of 24 GyE carbon ions in 3 GyE/
fraction (5 fractions per week) to the CTV1, we aim at
covering the CTV1 with the 95% prescription isodose.
CTV2 includes CTV1 with safety margins along typical
pathways of spread as well as the complete surgical
operational area. Locoregional nodal areas (levels II and
III) are also included within the CTV2, in case of radi-
ologically suspect lympüh nodes, further levels are
included as indicated. The CTV2 also takes account for
set-up variations, hence corresponds to the PTV2
(CTV2 = PTV2). 50 Gy IMRT (inversely planned step-
and-shoot or tomotherapy technique) in 25 fractions
(5 fractions per week) are prescribed to the CTV2 (cov-
erage at least with the 90% prescription isodose) taking
into account doses applied by daily image guidance with
MV-cone-beam CT.
Planning and RT treatment technique
Carbon ion therapy treatment planning is carried out
using a dedicated treatment planning system (TPS)
developed for and in co-operation with HIT(Heidelberg
ion therapy centre). TPS offers the following functional-
ities also expected in conventional radiation therapy as
well as methods for biological RT treatment optimiza-
tion. As ion beams exhibit an increased biological effec-
tive dose depending on various factors, these need to be
included within the planning algorithm. In addition,
steering parameters for scanned ion beams need also be
calculated by the TPS.
Carbon ion treatment is given at the HIT after inverse
treatment planning in active beam application (raster-
scanning method). A monoenergetic ion beam with a full-
width/half-maximum (FWHM) of 5mm is extracted from
the accelerator system (synchrotron) and magnetically
deflected to subsequently scan all planned iso-energetic
slices roughly corresponding to the tumour’s radiological
depth. Using this method almost any desired dose distri-
bution can be created.
Intensity-modulated RT is planned at two commercially
available planning systems: KonRad (Siemens OS) for step-
and-shoot applications or Tomotherapy
®.I M R Th e n c e
is delivered either at a 6 MV-linear accelerator (step-
and-shoot technique) or at a 6 MV tomotherapy unit.
Daily image guidance for carbon ion therapy consists
of orthogonal x-ray controls in treatment position, for
IMRT image guidance consists of MV cone-beam CTs.
Supportive therapy
Patients do not routinely receive prophylactic feeding
tubes, however if they uncommonly experience significant
weight loss we will of course offer feeding tube insertion
or parenteral feeding.
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After obtaining written informed consent, patients are
included into the trial and receive their treatment plan-
ning investigations. Treatment starts with 8 fractions
carbon ion (8 × 3 GyE C12) therapy followed by 27/28
fractions of IMRT corresponding to a total dose of
approximately 74 GyE (figure 1). Treatment duration is
approximately 6-7 weeks.
First follow-up examination including diagnostic, con-
trast-enhanced MRI will be carried out 6 weeks post
completion of RT. Further controls including MRI are 3,
6, and 12 months thereafter, in 6 monthly intervals until
2 years post RT.
Patients are also encouraged to undergo regular check-
ups incl. full ENT clinical examinations and/or ophthal-
mological examinations as applicable in regular intervals
(figure 2). Performance state (Karnofsky-Index), therapy-
associated side effects as well as potential intercurrent
therapy of each patient are recorded on follow-up.
Proteomics and Genomics
For the proteomic examinations 30 mL venous blood
will be collected from each subject prior to RT, at day
29, at completion of RT, and at the 1
st and 2
nd follow-
up visit. Thus, the overall volume of blood samples used
for Proteomic/Genomic investigations will be approxi-
mately 150 mL. Following parameters/pathways will be
investigated:
￿ In order to predict the efficacy of the therapy
blood will be collected during therapy and follow-up
to detect and correlate the levels of well known
tumour- and angiogenesis markers (VEGF, TGF-
Alpha, bFGF, IL8, k-ras, etc.) using Enzyme-Linked
Immunosorbent Assay (ELISA).
￿ Further, platelet protein content (i.e. tumor angio-
genesis growth factors and cytokines) will be ana-
lyzed using citrate blood samples and correlated
with serum- and plasma- protein results.
In order to perform the genomic analysis, patients’
blood samples are collected as indicated and RNA,
miRNA and DNA isolation will be performed. Based on
an established platform, linear RNA-amplification, label-
ling and hybridization on human genome wide oligo-
arrays (transcriptome analysis) are planned. DNA sam-
ples are used to identify potential chromosomal aberra-
tions or epigenetic alterations that might predict
treatment response. RNA and miRNA samples are
further analyzed by real time quantitative RT-PCR to
confirm microarray data and to test a subset of clinical
predictors.
The determinations of proteomic and genomic
parameters will be carried out at the Department of
Radiation Oncology in Heidelberg. No further genetic
investigations on the blood collected during the study
will be carried out.
Assessment of efficacy
Assessment of efficacy will be carried out by evaluation
of imaging studies (MRI) at each follow-up. If applicable
(in case of initial macroscopic tumour) tumour response
will be evaluated according to the RECIST-criteria [24].
Occurrence of distant metastases (date and site) is
recorded if applicable.
Trial organization/coordination
The IMRT-HIT-SNT trial has been designed by
the Department of Radiation Oncology, University of
Heidelberg, and is carried out at the Heidelberg Ion
Therapy Centre (HIT). It is an investigator-initiated
trial; the Department of Radiation Oncology is respon-
sible for co-ordination, overall trial management, regis-
tration (clinicaltrials.gov Identifier: NCT 01220752),
database management, quality assurance, monitoring,
and reporting.
Investigators
Patients are recruited by the Department of Radiation
Oncology.
Adverse events
Adverse and serious adverse events are recorded using
NCI common toxicity criteria for adverse events
(CTCAE v.4). Acute radiation effects are defined as
effects occurring within 90 days from beginning of
radiotherapy. Late effects are defined as effects observed
thereafter. Safety analysis is performed with respect to
frequency of serious adverse events and adverse events
stratified by organ system, severity, causality.
Figure 1 Trial flow chart.
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Patient accrual is completed with inclusion of the last
patient and should extend for approximately 4 years
from trial initiation. Regular trial participation for each
patient terminates 2 years post inclusion into the trial
or the patient’s death respectively.
Discontinuation of treatment
￿ Patient wish
￿ Medical condition necessitating treatment termina-
tion and withdrawal of the patient from the trial
￿ Pregnancy
￿ Lack of compliance
Premature termination of the trial
The trial can be prematurely closed or suspended by the
LKP in following cases:
￿ Medical or ethical reasons relevantly affecting the
risk-benefit relationship,
￿ Difficulties in recruitment of subjects suggest unjus-
tifiable prolongation of the study timeline,
￿ Previously unexpected adverse events (in respect of
their nature, severity, duration or outcome) occur with
unjustifiable frequency,
￿ Expected adverse events occur with an unexpectedly
high incidence,
￿ Relevant superiority of patients in one treatment
arm of a comparable clinical trial,
￿ Legal authorities’ decision
The Ethics Committee (EC) and the competent regu-
latory authorities will be informed about premature clo-
sure of the trial. Furthermore, the Ethics Committee(s)
and competent regulatory authorities themselves may
decide to stop or suspend the trial.
If the trial is closed prematurely, the trial material
such as completed, partially completed, and blank CRFs
will be returned to the coordinating investigator.
All involved investigators have to be informed imme-
diately about a cessation or suspension of the trial. The
decision is binding on all trial centers and investigators.
Ethics, informed consent, and safety
The final protocol was reviewed by the ethics committee
of the University of Heidelberg Medical School (S-319/
2009). The trial complies with the Helsinki Declaration
in its recent German version, the Medical Association’s
professional code of conduct, principles of Good Clinical
Practice (GCP) guidelines and the Federal Data Protec-
tion Act. It will be carried out in keeping with local
legal and regulatory requirements. It is also subject to
authorization by the German radiation protection
authority (Bundesamt für Strahlenschutz: = BfS). Medi-
cal confidentiality and Federal Data Protection Act will
be followed. Written informed consent is obtained from
each patient in oral and written form.
Discussion
Sinonasal tumours are rare malignancies of the nasal
cavity and paranasal sinuses. Preferred treatment would
generally be complete surgical resection. Due anatomical
site and proximity to critical structures surgical treat-
ment is very complex and clear margins are rarely
achieved. Therefore, the majority of patients will
undergo RT either because of involved surgical resection
margins or technical inoperability.
Outcome with adjuvant or definitive RT however has
so far been hampered by high rates of accompanying
toxicity. Modern radiotherapy techniques such as IMRT
a n di m a g e - g u i d e dR T( I G R T )h a v ei m p r o v e dt o x i c i t y .
Despite these sophisticated new techniques, it remains
challenging to apply sufficient doses to the tumour in
order to improve control rates.
This phase II trial was designed to evaluate the combina-
tion of 50 Gy IMRT plus 24 GyE carbon ion boost to a
total dose of 74 GyE with respect to toxicity and control
rates. To our knowledge, this is the first prospective trial
evaluating this treatment regimen in sinonasal cancers.
Author details
1Dept. of Radiation Oncology, INF 400, 69120 Heidelberg, Germany.
2Alcedis
GmbH, Winchester-Str. 2, 35394 Gießen, Germany.
Authors’ contributions
MWM, CWK, and JD developed the study protocol and planned the trial.
CWK is responsible for statistical considerations/basis of the trial. ADJ, AN,
MWM are responsible for conducting and co-ordination of the trial as well
as patient recruitment. All authors read and approved the final manuscript.
Figure 2 Follow-up.
Jensen et al. BMC Cancer 2011, 11:190
http://www.biomedcentral.com/1471-2407/11/190
Page 5 of 6Competing interests
The authors declare that they have no competing interests.
Received: 18 October 2010 Accepted: 22 May 2011
Published: 22 May 2011
References
1. Muir CS, Nectoux J: Descritptive epidemiology of malignant neoplasms of
nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol
Allied Sci 1980, 5:195-211.
2. Rousch G: Epidemiology of cancer of nose and paranasal sinus
carcinomas: current concepts. Head Neck Surg 1979, 2:3-11.
3. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W: Intensity-modulated
radiotherapy for sinonasal tumors: Ghent University Hospital update. Int
J Radiat Oncol Biol Phys 2009, 73:424-432.
4. Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N, et al: Primary
chemotherapy followed by anterior craniofacial resection and
radiotherapy for paranasal cancer. Ann Oncol 2003, 14:367-372.
5. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T: Nasal and
paranasal sinus carcinoma: are we making progress? A series of 220
patients and a systematic review. Cancer 2001, 92:3012-3029.
6. Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Million RR: Malignant
tumors of the nasal cavity and ethmoid and sphenoid sinuses. Int J
Radiat Oncol Biol Phys 1988, 14:11-22.
7. Shukovsky LJ, Fletcher GH: Retinal and optic nerve complications in a
high dose irradiation technique of ethmoid sinus and nasal cavity.
Radiology 1972, 104:629-634.
8. Brizel DM, Light K, Zhou SM, Marks LB: Conformatl radiation therpy
treatment planning reduces the dose to the optic structures for patients
with tumors of the paranasal sinuses. Radiother Oncol 1999, 51:215-218.
9. Huang D, Xia P, Akazawa P, Quivey JM, Verhey LJ, Kaplan M, et al:
Comparison of treatment plans using intensity-modulated radiotherapy
and three-dimensional conformal radiotherapy for paranasal sinus
carcinoma. Int J Radiat Oncol Biol Phys 2003, 56:158-168.
10. Lomax AJ, Goitein M, Adams J: Intensity modulation in radiotherapy:
photons versus protons in the paranasal sinus. Radiother Oncol 2003,
66:11-18.
11. Mock U, Georg D, Bogner J, Auberger T, Pötter R: Treatment planning
comparison of conventional, 3D conformal, and intensity-modulated
photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J
Radiat Oncol Biol Phys 2004, 58:147-154.
12. Chen AM, Sreeraman R, Mathai M, Vijayakumar S, Purdy JA: Potential of
helical tomotherapy to reduce dose to the ocular structures for patients
treated for unresectable sinonasal cancer. Am J Clin Oncol 2010.
13. Chera BS, Malyapa R, Louis D, Mendenhall WM, Li Z, Lanza DC, et al: Proton
therapy for maxillary sinus carcinoma. Am J Clin Oncol 2009, 32:296-303.
14. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V,
et al: Carcinomas of the paranasal sinuses and nasal cavity treated with
radiotherapy at a single institution over five decades: are we making
improvement? Int J Radiat Oncol Biol Phys 2007, 69:141-147.
15. Daly ME, Chen AM, Bucci MK, El-Sayed I, Xia P, Kapla MJ, et al: Intensity-
modluated radiation therapy for malignancies of the nasal cavity and
paranasal sinuses. Int J Radiat Oncol Biol Phys 2007, 67:151-157.
16. Hoppe BS, Wolden SL, Zelefsky MJ, Mechalakos JG, Shah JP, Kraus DH, et al:
Postoperative intensity-modulated radiation therapy for cancers of the
paranasal sinuses, nasal cavity, and lacrimal glands: technique, early
outcome, and toxicity. Head Neck 2008, 30:925-932.
17. Truong MT, Kamat UR, Liebsch NJ, Curry WT, Lin DT, Barker FG, et al: Proton
radiation therapy for primary sphenoid sinus malignancies: treatment
outcome and prognostic factors. Head Neck 2009, 31:1297-1308.
18. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu Aj, Wolden SL, et al:
Unresectable carcinoma of the paranasal sinuses: outcome and
toxicities. Int J Radiat Oncol Biol Phys 2008, 72:763-769.
19. Snyers A, Janssens GORJ, Twickler MB, Hermus AR, Takes RP, Kappelle AC,
et al: Malignant tumors of the nasal cavity and paranasal sinuses: long-
term outcome and morbidity with emphasis on hypothalamic-pituary
deficiency. Int j Radiat Oncol Biol Phys 2009, 73:1343-1351.
20. Dirix P, Nuyts S, Geussens Y, Jorissen M, Vander Poorten V, Fossion E, et al:
Malignancies of the nasal cavity and paranasal sinuses: long-term
outcome with conventional or three-dimensional conformal
radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:1042-1050.
21. Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK, et al: Patterns of
failure after combined-modality approaches incorporating radiotherapy
for sinonasal undifferentiated carcinoma of the head and neck. Int J
Radiat Oncol Biol Phys 2008, 70:338-343.
22. Thornton AF, Fitzek MM, Varvares M, Adams J, Rosenthal S, Pollock C, et al:
Acelerated, hyperfractionated proton/photon irradiation for advanced
paranasal sinus cancer: results of a prospective phase I-II study. Int J
Radiat Oncol Biol Phys 1998, 42:222-1027.
23. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled
Clinical Trials 1989, 10:1-10.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RA, Rubinstein L,
et al: New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst 2000, 92:205-216.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/190/prepub
doi:10.1186/1471-2407-11-190
Cite this article as: Jensen et al.: Treatment of malignant sinonasal
tumours with intensity-modulated radiotherapy (IMRT) and carbon ion
boost (C12). BMC Cancer 2011 11:190.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Jensen et al. BMC Cancer 2011, 11:190
http://www.biomedcentral.com/1471-2407/11/190
Page 6 of 6